Burjeel Holdings PLC, a leading private healthcare provider in the UAE, has announced a remarkable 129% year-on-year increase in net profit for the second quarter of 2025, reaching AED 148 million. This performance underscores the company’s strategic focus on high-value specialties, operational efficiency, and regional expansion.
Strong Financial Performance
The group’s revenue for Q2 2025 rose by 18.7% to AED 1.4 billion, driven by a 12.1% increase in patient footfall and higher patient yield. The EBITDA also saw significant growth, increasing by 59.4% to AED 306 million, with an expanded margin of 21.8%. This surge in profitability is attributed to enhanced operating leverage, margin expansion, and gains from asset optimization, including AED 72 million from the derecognition of lease liabilities following the acquisition of Dubai Medeor Hospital.
Strategic Expansion in Oncology
Oncology services remained a core growth driver, with revenue increasing by 36.7% in Q2 2025. Burjeel Holdings expanded its advanced cancer network by integrating Dubai’s Advanced Care Oncology Center and opening new Burjeel Cancer Institute clinics in Al Ain, Sharjah, and Oman. The launch of the UAE’s first dedicated cancer pharmacy further strengthened the oncology support infrastructure.
Operational Excellence
Inpatient footfall grew by 17.7% year-on-year, reflecting strong demand across key specialties and a ramp-up in elective surgeries post-Ramadan. Outpatient footfall accelerated to 12.0%, up from 5.2% in the previous quarter, driven by primary care and physiotherapy centers, along with robust demand in oncology, pediatrics, ophthalmology, and family medicine. Bed occupancy improved to 69%, up from 65% in the same period last year, indicating stronger utilization across the network.
Sustained Growth in Other Specialties
Other specialties also recorded solid gains in H1 2025, including urology (+18%), emergency medicine (+17%), cardiology (+16%), and gastroenterology (+13%). The Hospitals segment continued to drive group performance, contributing 89% of total revenue in Q2 2025. Revenue in this segment grew by 17.3% to AED 1.25 billion, supported by strong growth in patient volumes and sustained demand for complex care services.
Commitment to Shareholder Value
In May 2025, the Group declared a full-year dividend of AED 170 million for FY 2024, representing 47% of net profit. This reflects Burjeel Holdings’ commitment to delivering value to its shareholders while maintaining a strong balance sheet to support future growth initiatives.
